These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23319035)

  • 21. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
    Abdallah F; Mohamed G; Ibrahim M; El Tarabily M
    Am J Med Sci; 2018 May; 355(5):456-466. PubMed ID: 29753376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
    Perry CM
    Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C genotypes and subtypes in Saudi Arabia.
    Shobokshi OA; Serebour FE; Skakni L; Al-Saffy YH; Ahdal MN
    J Med Virol; 1999 May; 58(1):44-8. PubMed ID: 10223544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
    Schnell G; Tripathi R; Beyer J; Reisch T; Krishnan P; Lu L; Dekhtyar T; Hall C; Vilchez RA; Pilot-Matias T; Collins C
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6807-15. PubMed ID: 26282418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of mixed hepatitis C virus (HCV) genotypes among recently diagnosed dialysis patients with HCV infection.
    Al Balwi MA
    Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):712-6. PubMed ID: 21743215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
    Yokoyama S; Kawakami Y; Imamura M; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Takahashi S; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
    J Gastroenterol Hepatol; 2015 Feb; 30(2):337-44. PubMed ID: 25091289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy.
    Serpaggi J; Chaix ML; Batisse D; Dupont C; Vallet-Pichard A; Fontaine H; Viard JP; Piketty C; Rouveix E; Rouzioux C; Weiss L; Pol S
    AIDS; 2006 Jan; 20(2):233-40. PubMed ID: 16511416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication.
    Elkady A; Tanaka Y; Kurbanov F; Sugauchi F; Sugiyama M; Khan A; Sayed D; Moustafa G; Abdel-Hameed AR; Mizokami M
    J Med Virol; 2009 Jun; 81(6):1015-23. PubMed ID: 19382263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C.
    Yada M; Masumoto A; Yamashita N; Motomura K; Koyanagi T; Sakamoto S
    World J Gastroenterol; 2010 Mar; 16(12):1506-11. PubMed ID: 20333792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.
    Köse Ş; Senger SS; Ersan G; Çavdar G
    Clin Exp Nephrol; 2013 Feb; 17(1):115-9. PubMed ID: 22814955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.